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n the United States, >300 000 patients undergo coronary artery bypass grafts (CABG) surgery each year. 1 Despite achieving complete revascularization with CABG, only 85% of the internal mammary artery and 60% of saphenous vein grafts (SVG) remained patent after 10 years. 2 Occlusion of grafts may result in an acute coronary syndrome and current European Society of Cardiology and North American guidelines recommend an invasive approach (class 1-A) in the management of appropriately selected patients with a previous history of CABG. 3, 4 Several contemporary clinical studies report worse long-term outcomes of patients presenting with non-STsegment-elevation myocardial infarction (NSTEMI) with prior CABG as compared with those without previous CABG, [5] [6] [7] [8] although data are inconsistent. 9, 10 It is consistently reported in many clinical studies that patients with prior CABG are generally older, with worse demographic profiles and more complex and extensive coronary artery disease which may contribute to the higher mortality observed. [10] [11] [12] Data that examines the outcomes of percutaneous coronary intervention (PCI) separately in grafts and in native vessels in patients with prior CABG presenting with NSTEMI are limited. In an unselected cohort of 11 118 patients (including STEMI, NSTEMI, and stable angina patients) with prior CABG, PCI to grafts was associated with significantly higher mortality and major adverse cardiovascular event (MACE; MI, repeat revascularization) as compared with those who underwent PCI in native vessels at median 3 years follow-up. 13 By contrast, in another study of 47 557 patients with NSTEMI (8790 had prior CABG), the adjusted risk of bleeding and in-hospital mortality did not differ significantly between the 2 groups (with and without prior CABG). 14 However, no large contemporary study has compared outcomes after PCI in NSTEMI patients with and without previous CABG and in the latter, outcomes after PCI in native arteries against PCI to grafts. We, therefore, sought to describe the early (in-patient and 30 days) and late (1 year) outcomes of PCI in patients with and without a history of prior CABG presenting with NSTEMI in a large contemporary unselected national cohort from the database of the British Cardiovascular Intervention Society (BCIS). Outcomes were compared with the population with no history of prior CABG undergoing PCI for NSTEMI during the same study period.
METHODS
This study was a retrospective analysis of prospectively recorded national data for all patients that underwent PCI for NSTEMI in England and Wales from January 2007 to December 2014, and the data that support the findings of this study are available from the corresponding author on reasonable request. The BCIS collects data on all PCI procedures undertaken in the United Kingdom with data collection managed by the National Institute of Cardiovascular Outcomes Research. Data input is mandatory, as part of the formal revalidation process, for all independent operators in the United Kingdom. The BCIS database consists of 113 clinical, procedural and outcome variables with ≈80 000 new reports added each year. [15] [16] [17] [18] We used data from the Office of National Statistics for mortality tracking in all patients of England and Wales by using their unique National Health Service number. We excluded patients from Scotland to Northern Ireland because of the absence of the Office of National Statisticslinked mortality data. Institutional research and ethical board approval were not required for this study as all data were anonymized and routinely collected as part of the national audit, but the project was approved by a national Data and Monitoring Advisory Group on behalf of National Institute of Cardiovascular Outcomes Research and BCIS.
Data were collected on patients' clinical characteristics, risk factors, and comorbid conditions, as well as aspects of interventional treatment and adjunctive drug therapy. We collected all-cause mortality during index admission and at 30-day and 1-year follow-up. In addition, we assessed temporal changes in interventional practice for these patients from 2007 to 2014. We also analyzed in-hospital MACE (defined as a composite of in-hospital mortality, in-hospital myocardial reinfarction, and target vessel revascularization), in-hospital major bleeding (described as arterial access site complication requiring surgery, gastrointestinal bleed, intracerebral bleed, retroperitoneal hematoma, and blood or platelets transfusion), and in-hospital stroke which included ischemic or hemorrhagic stroke or transient ischemic attack.
The study participants were divided into 3 groups: (group 1) no prior CABG, (group 2) previous CABG with PCI to native coronary arteries, and (group 3) previous CABG with PCI to bypass grafts. Patients with missing data for mortality, sex, and age were excluded. We compared clinical characteristics across the 3 groups of interest, and these comparisons were undertaken using Fisher exact tests for categorical and ANOVA for continuous variables. We used multiple imputations with chained equations to impute data for all variables with missing information.
WHAT IS KNOWN
• There are limited data about outcomes of non-STsegment-elevation myocardial infarction patients with prior coronary artery bypass grafts who undergo percutaneous coronary intervention.
WHAT THE STUDY ADDS
• This large study found that patients with prior coronary artery bypass graft are older and have more comorbid conditions and adverse clinical profile than noncoronary artery bypass graft patients having percutaneous coronary intervention.
• After adjustment for baseline differences, patients with previous coronary artery bypass graft are not at increased risk of mortality and major adverse cardiovascular events.
We registered age, sex, group of participants, and study outcomes as complete variables in imputation models and these were used to produce 10 datasets on which we ran the analysis. Almost 48% of data were missed in a variable of left ventricular ejection fraction, 14% in the family history of coronary artery disease, 10% in prior history of smoking and MI, and <10% in all remaining variables (Table 1) . Missing data can impair the ability to make correct inferences from observational studies. Complete case analysis is commonly applied, but it reduces sample size and may lead to reduced statistical power. However, by using multiple imputation methods, the sample size is preserved, and they are generally regarded as the preferred analysis technique. We used multiple imputations with chained equations to impute missing data. It is already well reported in the literature that multiple imputation is the best technique among all missing-ness mechanisms and works well even high level of data is missing. 19 For more clarity, we reported statistical models with complete case analysis, as well as with multiple imputations. We also applied multiple imputations with propensity score matching statistical techniques (mi estimate: teffects psmatch) to estimate the average treatment effects for adjustment of baseline differences across the groups of patients. We applied 2 different multiple imputation logistic regressions models to calculate propensity score for each group member: (1) PCI to native coronary arteries without prior CABG (group 0) versus PCI to native arteries in patient with prior CABG (group 1) and (2) PCI to native arteries without prior CABG (group 0) versus PCI to grafts (group 2). These scores were then applied to perform the matching, and simple logistic regression analysis was run (the sole predictor being group membership) to gain the average treatment effect.
We also performed Kaplan-Meier survival analysis and Cox proportional hazards regression analysis for 30-day and 1-year mortality by patients group. Stata 13.1 statistical package was used for statistical analysis.
RESULTS

Study Cohort
Our study cohort comprises 205 039 patients who had PCI during admission for NSTEMI in England and Wales from January 2007 to December 2014 and did not have missing data for mortality, follow-up, sex, and age. The process of patients' inclusion and exclusion is presented in Figure 1 . A total 186 670 (91%) patients had no history of prior CABG, whereas 18 369 (9%) had a history of previous CABG. In those patients with a history of prior CABG, 48% (n=8825) underwent PCI to native coronary arteries and 52% (n=9544) had PCI to bypass grafts. The mean follow-up of these patients was 3.84 years (SD=2.3), and 94% were followed-up for a minimum of 1 year (or until death, if occurring within this period).
Clinical Characteristics
Significant differences in demographic, clinical, and procedural characteristics of the 3 groups (Table 1) were observed. Specifically, patients with prior CABG were significantly older, less likely to be female, had a higher prevalence of diabetes mellitus, hypertension, hyperlipidemia, PVD, and previous MI or stroke (Table 1) . Patients with prior CABG were also more likely to have moderate-severe left ventricle systolic dysfunction as compared with those without previous CABG. A steady increase in use of drug-eluting stents was observed among all 3 groups from 2007 to 2014 ( Figure I in the Data Supplement). In 2007, 54%, 60%, and 57% drug-eluting stents were used in groups 1, 2, and 3, which increased to 88%, 84%, and 83%, respectively, in 2014. More patients in group 3 (25%) received glycoprotein IIb/IIIa inhibitor as compared with others (group 2, 16%; group 1, 21%), which may indicate the higher adverse clinical profile of this cohort, and the greater thrombotic environment encountered in SVGs. In group 2, a higher proportion of patients received left main stem and multivessel PCI (group 2=26% and 19%, group 1=3% and 16 %, and group 3=1.55% and 17%), presented with cardiogenic shock (group 2=1.5%, group 1=1.2%, and group 3=1%) and received circulatory support (group 2=2.7%, group 1=1.6%, and group 3=1.8%). In group 3, more patients were treated with thrombus aspiration (group 3=7.4%, group 1=4.6%, and group 2=2.4%) and DPDs (group 3=18%, group 1=0.4, and group 2=1.3%). Overall, patients in group 2 and 3 had higher-risk clinical and procedural profile as compared with those patients in group 1. Figure 2 demonstrates the temporal patterns of interventional practice from 2007 to 2014.
Unadjusted Outcomes
There were significant differences in unadjusted clinical outcomes (mortality and in-hospital MACE) among the 3 groups (Table 2) . Unadjusted Kaplan-Meier survival estimates for all 3 groups at 30 days and 1 year are shown in Figure 3 . Group 2 patients (patients with previous CABG and PCI to native coronary arteries) had the highest mortality at 30 days (2.6%) and at 365 days (8.29%) as compared with those who had group 3 (PCI to grafts; 1.9% and 7.08%; P=0.001 and 0.002) and group 1 (PCI to native coronary arteries without prior CABG; 1.7% and 4.8%; P<0.0001), respectively (Table 2 ). In-hospital MACE rates showed similar patterns.
Outcomes After Risk Adjustment
The adjusted risk of mortality, MACE, major bleeding, and stroke outcomes are presented in Table 3 . As a large age difference was observed among 3 groups, we also undertook statistical analysis just controlling for age to compare the impact of the other risk factors (Table II in 
Analysis With Propensity Score Matching
Finally, we undertook a propensity score matching analysis. We did not observe any difference in outcomes among patients with or without prior CABG where PCI was performed in either the native coronary arteries or in the grafts (Table 4) . Propensity score matching diagnostics success is presented in Table I and Figure IIA and IIB in the Data Supplement and it shows that groups are balanced across all covariates after matching.
DISCUSSION
To the best of our knowledge, this is the largest study to examine temporal trends, baseline clinical, and procedural characteristics and outcomes in patients with a history of prior CABG presenting with NSTEMI and undergoing PCI. Our study demonstrates that patients with prior CABG are older with a greater comorbid burden and more complex procedural characteristics, but after adjustment of these differences, clinical outcomes were similar to patients undergoing PCI for NSTEMI without prior CABG.
In our unadjusted analysis, patients with a history of CABG who underwent PCI to native coronary arteries (group 2) had the highest in-patient, 30-day and 1-year mortality, and in-patient MACE as compared with those patients who had PCI in grafts (group 3), or in native arteries without prior history of CABG (group 1). We observe that patients with prior CABG are a higherrisk cohort, with a greater burden of comorbidities and adverse clinical profile, which might contribute to the unfavorable outcomes observed in unadjusted analyses. For example, patients with prior CABG were more likely to present with cardiogenic shock, undergo PCI to the left main stem, or multivessel PCI and were more often in receipt of circulatory support. After adjustment of such confounding factors, no statistically significant differences in clinical outcomes were observed in patients with or without previous CABG, regardless whether the PCI was performed in a native vessel or a graft, in the majority of the analyses although we did observe a reduced risk of 30-day mortality in some of the analyses that we undertook in the cohort of patients that had PCI in grafts (group 3). Although this is statistically significant, whether this observation is clinically significant is unclear, and it may relate to selection bias in that PCI is undertaken with a much higher threshold in patients with lesions in the SVG (undertaken in relatively healthier patients) compared with those with lesions in coronary native vessels. Indeed, previous studies have suggested that patients with prior CABG presenting with NSTEMI are less likely to receive early invasive treatment. 20 For example, Kim et al 14 reported in a study of 47 557 NSTEMI patients, that prior CABG surgery was independently associated with a lower likelihood of early invasive coronary angiography (adjusted OR, 0.88; CI, 0.83-0.92). Similar findings were reported in the CRUSADE Quality Improvement Initiative (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines), where high-risk patients were paradoxically less likely to receive invasive therapies, despite having greater potential to get more benefit from a more aggressive approach. 21 Such clinical practices might be driven by the paucity of data in NSTEMI patients with previous CABG undergoing PCI, or the perceived greater risk of adverse outcomes in such patients because of their higher-risk clinical profile.
Despite current guidelines recommending the use of DPD in PCI to vein grafts, we observed a relatively small proportion of patients (18%) receiving this adjunctive intervention. However, this finding is consistent with other observational studies. For instance, in the United States, use of DPD was limited to 21% of patients in National Cardiovascular Data registry. 22 Similar findings were reported by Brennan et al 23 in a study of 49 325 patients with SVG lesions, when one-third of the centers in the United States did not use DPD at all and only 5.6% used DPD in >50% of SVG PCI. There are several possible explanations for less use of these adjunctive devices in vein grafts PCI. For example, current devices are still [24] [25] [26] However, these techniques have not been studied in well-designed randomized controlled clinical trials. 27 Nevertheless, more compelling data are needed which can evaluate the performance of DPD and other modern interventional techniques in randomized clinical trials to prevent distal embolization in vein grafts PCI. Studies describing outcomes in patients presenting with NSTEMI and a prior history of CABG have reported variable findings, although such prior studies have not focused specifically according to whether the PCI was undertaken in a native vessel or graft vessel in this cohort of patients with prior CABG. In a study of 47 557 patients presenting with NSTEMI, in which 8790 patients had prior CABG, the adjusted risk of bleeding and inhospital mortality did not differ significantly between the prior CABG and no CABG group, although this study included patients managed both medically and invasively with PCI 14 and reported no long-term follow-up data. Data from the CathPCI Registry reported that in patients with prior CABG, most PCI was performed in native coronary arteries and PCI of a bypass graft was independently associated with in-hospital mortality, 11 28 Data derived from the National Cardiovascular Data Registry of 11 118 patients with prior CABG showed that the majority of PCI procedures in this cohort of patients were performed in native coronary arteries (73%) and the rest in bypass grafts. In the multivariable analysis, significantly higher mortality (HR, 1.3; CI, 1.18-1.42), MI (HR, 1.61; CI, 1.43-1.82), and repeat revascularization (HR, 1.60; CI, 1.5-1.7) were observed in patients who received PCI in grafts at a median follow-up of 3.1 years. However, this study did not report outcomes specifically for NSTEMI.
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Strengths and Limitations
This study has several strengths. The BCIS dataset comprises almost a complete record of all PCI procedures undertaken in the United Kingdom, which represent unselected real-world experience, containing high-risk patients with multiple comorbidities often not included in clinical trials, and it represents the largest analysis of PCI for NSTEMI patients with prior CABG to be published. 29 To the best of our knowledge, no national cohort study has examined clinical outcomes in NSTEMI patients with the previous history of CABG who undergo PCI to grafts or native arteries and compared with those who did not have CABG. Our large sample size gives us sufficient statistical power to capture differences in clinical outcomes between the patient grouped studied. Furthermore, given patients with prior CABG are often excluded or under-represented in landmark PCI trials, and so our data represent the best available current evidence in this cohort. A major inherent limitation of our study was that it was based on a retrospective analysis of national registry data and hence was subject to all the limitations of observational studies. Second, although mortality tracking within England and Wales is well structured, all other clinical outcomes and postprocedural complication are self-reported without official adjudication. Therefore, such outcomes are vulnerable to reporting biases, and complications may be under-reported, although it is unlikely that there will be differences in such reporting biases in the 3 groups studied. Third, this dataset does not contain information about patients who were admitted with NSTEMI but who were managed medically or underwent cardiac catheterization and no PCI was performed. Therefore, our findings are only applicable to patients who undergo PCI and cannot be used to inform around outcomes in the wider cohort of NSTEMI patients. Finally, BCIS dataset does not record information about the nature of grafts (arterial or venous), although it is likely that the majority of PCI was performed in SVGs, as previous data derived from the National Cardiovascular Data Registry reported that arterial grafts represented only 2.5% of all PCI procedures undertaken in bypass grafts in the United States.
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Conclusions
Our study demonstrates that close to 1 in 11 patients who present with NSTEMI and undergo PCI are patients with prior CABG. These patients are a higher risk group that are older, have more comorbid conditions, and present with more hemodynamic compromise. However, after adjustment of differences in baseline clinical and procedural characteristics, we report that clinical outcomes are not significantly different in patients who undergo PCI to the grafts or native vessels when compared with those patients that have not had prior CABG. Although PCI to bypass grafts is technically more demanding and complex, our study demonstrates reassuring data for short and medium-term clinical outcomes-the presence of prior CABG should not be a factor in deciding on invasive management after presentation with NSTEMI. Our study suggests that the excess of cardiac events and death seen in patients with prior CABG relates more to the comorbid burden of the patients than to the fact that coronary intervention itself increases risk of these events.
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